TITLE

Impact of Risk Factors for Specific Causes of Death in the First and Subsequent Years of Antiretroviral Therapy Among HIV-Infected Patients

AUTHOR(S)
Ingle, Suzanne M.; May, Margaret T.; Gill, M. John; Mugavero, Michael J.; Lewden, Charlotte; Abgrall, Sophie; Fätkenheuer, Gerd; Reiss, Peter; Saag, Michael S.; Manzardo, Christian; Grabar, Sophie; Bruyand, Mathias; Moore, David; Mocroft, Amanda; Sterling, Timothy R.; D'Arminio Monforte, Antonella; Hernando, Victoria; Teira, Ramon; Guest, Jodie; Cavassini, Matthias
PUB. DATE
July 2014
SOURCE
Clinical Infectious Diseases;Jul2014, Vol. 59 Issue 2, p287
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Among HIV-infected patients who initiated antiretroviral therapy (ART), patterns of cause-specific death varied by ART duration and were strongly related to age, sex, and transmission risk group. Deaths from non-AIDS malignancies were much more frequent than those from cardiovascular disease.Background. Patterns of cause-specific mortality in individuals infected with human immunodeficiency virus type 1 (HIV-1) are changing dramatically in the era of antiretroviral therapy (ART).Methods. Sixteen cohorts from Europe and North America contributed data on adult patients followed from the start of ART. Procedures for coding causes of death were standardized. Estimated hazard ratios (HRs) were adjusted for transmission risk group, sex, age, year of ART initiation, baseline CD4 count, viral load, and AIDS status, before and after the first year of ART.Results. A total of 4237 of 65 121 (6.5%) patients died (median, 4.5 years follow-up). Rates of AIDS death decreased substantially with time since starting ART, but mortality from non-AIDS malignancy increased (rate ratio, 1.04 per year; 95% confidence interval [CI], 1.0–1.1). Higher mortality in men than women during the first year of ART was mostly due to non-AIDS malignancy and liver-related deaths. Associations with age were strongest for cardiovascular disease, heart/vascular, and malignancy deaths. Patients with presumed transmission through injection drug use had higher rates of all causes of death, particularly for liver-related causes (HRs compared with men who have sex with men: 18.1 [95% CI, 6.2–52.7] during the first year of ART and 9.1 [95% CI, 5.8–14.2] thereafter). There was a persistent role of CD4 count at baseline and at 12 months in predicting AIDS, non-AIDS infection, and non-AIDS malignancy deaths. Lack of viral suppression on ART was associated with AIDS, non-AIDS infection, and other causes of death.Conclusions. Better understanding of patterns of and risk factors for cause-specific mortality in the ART era can aid in development of appropriate care for HIV-infected individuals and inform guidelines for risk factor management.
ACCESSION #
96950288

 

Related Articles

  • The Impact of Opiate Substitution Therapy and Highly Active Antiretroviral Therapy on Mortality Risk Among People Who Inject Drugs. Hickman, Matthew; Vickerman, Peter; Degenhardt, Louisa // Clinical Infectious Diseases;10/1/2015, Vol. 61 Issue 7, p1166 

    The authors discuss the impact of opiate substitution therapy and antiretroviral therapy on mortality risk in people who inject drugs (PWID). Topics discussed include role of opioid substitution therapy in reducing the risk of HIV transmission among PWID, role of antiretroviral therapy in...

  • ART prevented HIV transmission in serodiscordant couples.  // Infectious Disease News;Jan2013, Vol. 26 Issue 1, p8 

    The article presents a study conducted by Chinese researchers, which showed that providing antiretroviral therapy (ART) to the HIV-positive partner in a serodiscordant couple lowered the rate of HIV transmission to the uninfected partner.

  • Liver and heart deaths down in Europe/US HIV study, but not non-AIDS cancers.  // HIV Treatment ALERTS!;Nov2014, p21 

    The article reports on a study which reveals that liver and heart-related deaths have decreased, while deaths due to cancer have increased in large HIV group in the U.S. and Europe. The falling death rate among HIV-positive people is attributed to antiretroviral therapy. It also implies that...

  • The Spectrum projection package: improvements in estimating mortality, ART needs, PMTCT impact and uncertainty bounds. Stover, J; Johnson, P; Zaba, B; Zwahlen, M; Dabis, F; Ekpini, H E // Sexually Transmitted Infections;Aug2008 Supplement 1, Vol. 84 Issue S1, pi24 

    Background: The approach to national and global estimates of HIV/AIDS used by UNAIDS starts with estimates of adult HIV prevalence prepared from surveillance data using either the Estimation and Projection Package (EPP) or the Workbook. Time trends of prevalence are transferred to Spectrum to...

  • HIV transmission in serodiscordant heterosexual couples. Boily, Marie-Claude; Buvé, Anne; Baggaley, Rebecca F. // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;5/29/2010, Vol. 340 Issue 7757, p1149 

    The authors comment on a study discussed within the issue which estimated the risk of heterosexual transmission of HIV-1 from infected patients taking combined antiretroviral treatment. As stated, participants were assigned to immediate antiretroviral treatment or deferred treatment when their...

  • Switzerland: Statement on sexual transmission of HIV by people on ART. Pearshouse, Richard // HIV/AIDS Policy & Law Review;Jul2008, Vol. 13 Issue 1, p37 

    The article reports that Swiss AIDS experts have issued a statement concluding that HIV-positive individuals who are on effective antiretroviral therapy (ART) and who do not have any sexually transmitted infections (STI) cannot transmit HIV through sexual contact. The experts reviewed studies of...

  • Pre-exposure prophylaxis in HIV. Khambhati, Ravi; Singhal, Priyanka; Marfatia, Y. S. // Indian Journal of Sexually Transmitted Diseases;2009, Vol. 30 Issue 2, p127 

    The article presents abstracts on medical topics which include a study on the use of HIV pre-exposure prophylaxis (HIV-PrEP) in HIV prevention, the efficacy of combined Tenofovir and Emtricitabine as HIV-PrEP to reduce the risk of HIV transmission in the U.S., and the impact of antiretroviral...

  • Global: clinical trial shows dramatic reduction in transmission of HIV as a result of treatment. Cozac, David // HIV/AIDS Policy & Law Review;Oct2011, Vol. 15 Issue 3, p31 

    The article reports on a clinical trial conducted by the U.S. HIV Prevention Trials Network which revealed that human immunopdeficiency virus (HIV)-positive persons' adherence to an effective antiretroviral therapy reduce the risk of virus transmission by 96 percent. The trial confirmed that HIV...

  • Access to HIV/AIDS therapy widens down under.  // PharmacoEconomics & Outcomes News;6/18/2005, Issue 480, p18 

    Reports on the decision of the New Zealand drug funding agency Pharmac to provide HIV-positive persons access to the fixed combination antiretroviral agent lopinavir/ritonavir Kaletra. Plan of the agency to extend the use of antiretrovirals to help prevent mother-to-child transmission of HIV...

Share

Read the Article

Courtesy of

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics